Skip to main content
Year archive

DBV Technologies — 2025 filings

All 72 regulatory filings released by DBV Technologies (DBV) in 2025, sourced directly from the official regulator.

72 Filings
2025 Period
2025 filings (72)
Filing Released Lang
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Earnings Release Q4 2025
2025-12-16 English
DBV Technologies annonce des résultats préliminaires positifs dans l’étude de phase 3 VITESSE sur le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques à l’arachide
Earnings Release Q4 2025
2025-12-16 French
Franchissements de seuils
Major Shareholding Notification
2025-11-17 French
Franchissement de seuils
Major Shareholding Notification
2025-11-13 French
Franchissement de seuils
Regulatory Filings
2025-11-13 French
DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides
Regulatory Filings
2025-11-12 French
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Regulatory Filings
2025-11-12 English
DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation
Regulatory Filings
2025-11-04 French
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Regulatory Filings
2025-11-04 English
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration
Board/Management Information
2025-10-30 French
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Board/Management Information
2025-10-30 English
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Regulatory Filings
2025-10-30 English
DBV Technologies participe au congrès scientifique annuel de l'ACAAI
Regulatory Filings
2025-10-30 French
DBV Technologies Reports Third Quarter 2025 Financial Results
Interim / Quarterly Report 9M 2025
2025-10-28 English
DBV Technologies publie ses résultats financiers du troisième trimestre 2025
Interim / Quarterly Report 9M 2025
2025-10-28 French
Franchissement de seuils
Major Shareholding Notification
2025-10-20 French
Franchissement de seuils
Major Shareholding Notification
2025-10-14 French
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq
Capital/Financing Update
2025-10-06 French
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Capital/Financing Update
2025-10-06 English
DBV Technologies annonce la démission d’un membre de son Conseil d’administration
Board/Management Information
2025-09-18 French
DBV Technologies Announces Resignation of Board Member
Board/Management Information
2025-09-18 English
DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq
Capital/Financing Update
2025-09-05 French
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
Capital/Financing Update
2025-09-05 English
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Investor Presentation
2025-09-03 English
DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment
Regulatory Filings
2025-09-03 French
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2025
Share Issue/Capital Change
2025-08-01 French
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-08-01 English
DBV Technologies announces filing of 2025 Half-Year Report ? Conditions for accessing or consulting the Report
Report Publication Announcement
2025-07-29 English
DBV Technologies publie son Rapport Financier Semestriel 2025 ? Modalités de mise à disposition ou de consultation
Report Publication Announcement
2025-07-29 French
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
Interim / Quarterly Report H1 2025
2025-07-29 English
DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025
Interim / Quarterly Report H1 2025
2025-07-29 French
Rapport financier semestriel
Interim / Quarterly Report H1 2025
2025-07-29 French
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
Regulatory Filings
2025-07-28 French
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Net Asset Value
2025-07-28 English
DBV Technologies annonce la nomination de James Briggs au poste de Directeur des Ressources Humaines
Board/Management Information
2025-07-22 French
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
Board/Management Information
2025-07-22 English
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
Regulatory Filings
2025-06-25 English
Franchissement de seuils
Major Shareholding Notification
2025-06-20 French
Franchissement de seuils
Major Shareholding Notification
2025-06-17 French
DBV Technologies to Participate in Upcoming EAACI Congress 2025
Regulatory Filings
2025-06-12 English
DBV Technologies participera au prochain congrès EAACI 2025
Regulatory Filings
2025-06-12 French
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025
AGM Information
2025-06-11 French
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Declaration of Voting Results & Voting Rights Announcements
2025-06-11 English
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-06-04 English
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 mai 2025
Declaration of Voting Results & Voting Rights Announcements
2025-06-04 French
DBV Technologies publie un amendement à son Document d’enregistrement universel 2024
Remuneration Information
2025-06-03 French
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
Report Publication Announcement
2025-06-03 English
Assemblée Générale Mixte du 11 juin 2025
AGM Information
2025-05-15 French
Combined General Meeting of June 11, 2025
AGM Information
2025-05-15 English
Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2025
Declaration of Voting Results & Voting Rights Announcements
2025-05-06 English
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025
Declaration of Voting Results & Voting Rights Announcements
2025-05-06 French
DBV Technologies participera à la conférence Citizens JMP Life Sciences
Regulatory Filings
2025-05-05 French
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
Regulatory Filings
2025-05-05 English
DBV Technologies publie ses résultats financiers du 1er trimestre 2025
Interim / Quarterly Report Q1 2025
2025-04-30 French
DBV Technologies Reports First Quarter 2025 Financial Results
Interim / Quarterly Report Q1 2025
2025-04-30 English
Franchissement de seuils
Director's Dealing
2025-04-15 French
Franchissement de seuils
Major Shareholding Notification
2025-04-15 French
DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2024
Report Publication Announcement
2025-04-11 French
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
Report Publication Announcement
2025-04-11 English
Document d'enregistrement universel 2024
Annual Report (ESEF) FY 2024
2025-04-11 French
Franchissement de seuils
Major Shareholding Notification
2025-04-04 French
Franchissement de seuils
Major Shareholding Notification
2025-04-03 French
DBV Technologies Annonce un Financement pouvant atteindre 306,9 millions de dollars (284,5 millions d’euros) permettant d’avancer le programme Viaskin® Peanut jusqu’au dépôt d'une Demande de Licence B
Capital/Financing Update
2025-03-28 French
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
Capital/Financing Update
2025-03-28 English
DBV Technologies conclut un accord avec la FDA sur les données d'innocuité requises pour la demande de BLA du patch Viaskin® Peanut chez les enfants de 4-7 ans, accélérant ainsi au premier semestre 20
Earnings Release FY 2024
2025-03-24 French
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Rep
Earnings Release FY 2024
2025-03-24 English
DBV Technologies participera au prochain congrès conjoint AAAAI/WAO
Regulatory Filings
2025-02-25 French
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
Investor Presentation
2025-02-25 English
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Capital/Financing Update
2025-01-13 English
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
Transaction in Own Shares
2025-01-13 French
DBV Technologies présente les résultats positifs à 3 ans de l'étude de prolongation en ouvert d 'EPITOPE, étude clinique de phase 3
Legal Proceedings Report
2025-01-08 French
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study
Earnings Release H1 2024
2025-01-08 English